Björkhem I, Blomstrand S, Glaumann H, Strandvik B
Pediatr Res. 1985 Jun;19(6):590-3. doi: 10.1203/00006450-198506000-00018.
The cerebro-hepato-renal syndrome of Zellweger is a fatal hereditary disease and most of the affected infants die before the age of 6 months. Most probably the fatal outcome of the disease is due to an apparent complete lack of peroxisomes in the liver, kidneys, and brain. Treatment with clofibrate is known to increase drastically the number of peroxisomes in mammalian liver. We therefore treated two infants with the Zellweger syndrome with clofibrate (30 and 45 mg/kg body weight, respectively) for 3-4 wk. No clinical effect of the treatment was observed in any of the two cases, and the pattern of abnormal bile acids in serum did not change. No peroxisomes could be detected by electron microscopy of liver biopsies taken immediately after the treatment. Our failure to induce peroxisomes in the two Zellweger patients is in accord with the hypothesis that the protein missing in this autosomal recessive disease is absolutely essential for the formation of peroxisomes.
泽尔韦格脑肝肾综合征是一种致命的遗传性疾病,大多数患病婴儿在6个月前死亡。该疾病的致命后果很可能是由于肝脏、肾脏和大脑中明显完全缺乏过氧化物酶体。已知用氯贝丁酯治疗可大幅增加哺乳动物肝脏中过氧化物酶体的数量。因此,我们用氯贝丁酯(分别为30和45毫克/千克体重)对两名患有泽尔韦格综合征的婴儿进行了3 - 4周的治疗。在这两个病例中均未观察到治疗的临床效果,血清中异常胆汁酸的模式也未改变。治疗后立即进行的肝脏活检的电子显微镜检查未检测到过氧化物酶体。我们未能在两名泽尔韦格患者中诱导出过氧化物酶体,这与以下假设一致:在这种常染色体隐性疾病中缺失的蛋白质对于过氧化物酶体的形成绝对至关重要。